A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer

(2017) W. L. Akerley et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

(2011) M. Reck et al.   ANNALS OF ONCOLOGY

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients

(2010) P. M. Ellis et al.   CLINICAL CANCER RESEARCH

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

(2009) A. du Bois et al.   ANNALS OF ONCOLOGY

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

(2009) K. Mross et al.   CLINICAL CANCER RESEARCH

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

(2008) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY